Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
One Percent Rule Checklist For Safer Forex Trading Risk 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
LEIDEN, the Netherlands, April 20, 2017 -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that Gerard Platenburg, Chief Innovation Officer, will present at the 42nd Annual Deutsche Bank Health Care Conference on Wednesday, May 3, 2017 at 12:50pm ET. The conference is being held at the InterContinental Boston Hotel in Boston, MA, USA.
The live and archived webcast of the presentation will be accessible from the ‘Investor Relations’ section of ProQR’s website (www.proqr.com) under ‘Events and Presentations’. The archived webcasts will be available for 30 days following the presentation date.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases such as cystic fibrosis, Leber’s congenital amaurosis Type 10 and dystrophic epidermolysis bullosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*
Contact:
Smital Shah
Chief Financial Officer
T: +1 415 231 6431
[email protected]
